Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -2.20
- Piotroski Score 4.00
- Grade Neutral
- Symbol (FATE)
- Company Fate Therapeutics, Inc.
- Price $3.50
- Changes Percentage (-1.96%)
- Change -$0.07
- Day Low $3.48
- Day High $3.80
- Year High $8.83
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $7.50
- High Stock Price Target $145.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.92
- Trailing P/E Ratio -1.92
- Forward P/E Ratio -1.92
- P/E Growth -1.92
- Net Income $-160,928,000
Income Statement
Quarterly
Annual
Latest News of FATE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Diamondbacks rout Padres 11-2, await Mets-Braves doubleheader to find out playoff fate
In their regular-season finale, the Arizona Diamondbacks defeated the San Diego Padres 11-2, with Ketel Marte's two-run homer sealing the win. Arizona's playoff fate depends on the outcome of a makeup...
By AP NEWS | 1 day ago -
Israel strikes Beirut suburb, Nasrallah's fate unclear after Friday's massive attack
By Maya Gebeily, Timour Azhari and James MackenzieBEIRUT/JERUSALEM (Reuters) -Israel launched airstrikes on Beirut's southern suburbs and other areas of Lebanon on Saturday, a day after carrying out a...
By Reuters | 2 days ago -
Israel launches fresh assault on Beirut as uncertainty surrounds fate of Hezbollah leader
Israel launched a series of attacks on Beirut, targeting Hezbollah leader Hassan Nasrallah. The strikes caused significant destruction and casualties, escalating tensions in the region. The conflict r...
By The Guardian | 2 days ago
